MedTrace Logo

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-05-29

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Conditions

  • Dry Eye Disease (DED)

Interventions

OTHER

Artificial Tear Run-in

Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.

DRUG

licaminlimab

Licaminlimab eye drops three times daily (TID) for 29 days.

OTHER

Vehicle of licaminlimab

Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.

Sponsors & Collaborators

  • Oculis

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07548632 on ClinicalTrials.gov